Mmp-9 immunoreactivity in acute migraine.
作者信息
Leira Rogelio, Sobrino Tomás, Rodríguez-Yáñez Manuel, Blanco Miguel, Arias Susana, Castillo José
机构信息
Headache and Stroke Unit and Neurovascular Research Laboratory, Department of Neurology, Hospital Clínico Universitario, University of Santiago de Compostela, Spain.
出版信息
Headache. 2007 May;47(5):698-702. doi: 10.1111/j.1526-4610.2006.00641.x.
OBJECTIVE
To examine the role of matrix metalloproteinase 9 (MMP-9) in migraine during headache and asymptomatic periods.
METHODS
Thirty-four patients with migraine with and without aura (according to International Headache Society criteria) were studied. Clinical characteristic of headache were recorded. Blood samples for measurement of MMP-9 were drawn during headache attacks and during asymptomatic periods in all patients and in 10 healthy controls.
RESULTS
We found higher plasma MMP-9 levels in migraine patients than in control group (129.3 [78.0-258.9] vs. 49.6 [39.1-64.3] ng/mL; P < .001). Migrainous patients showed higher MMP-9 plasma levels during headache attacks than in asymptomatic periods, both in migraine without aura (338.4 [275.1-396.2] vs. 118.2 [75.3-137.5] ng/mL; P < .0001), and migraine with aura (389.3 [273.4-487.1] vs. 139.3 [107.3-191.4] ng/mL; P < .0001).
CONCLUSIONS
Our study showed an increased production of MMP-9 during migraine attacks. These data suggest a possible role of inflammation or blood-brain barrier disruption during the migraine attack.
Zotero 插件